It’s time to rethink peer review policies—and consider an “Earth Shot Program”

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

At a recent NIH study section that I chaired, we had many applications that we reviewed as a group before the meeting. At the meeting, we were required to discuss over 50% of the grants.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Wafik S. El-Deiry, MD, PhD, FACP
Director, Joint Program in Cancer Biology, Brown University and Lifespan Cancer Institute
Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University
American Cancer Society Research Professor

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Wafik S. El-Deiry, MD, PhD, FACP
Director, Joint Program in Cancer Biology, Brown University and Lifespan Cancer Institute
Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University
American Cancer Society Research Professor

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login